- Home
- KURA vs ABUS Comparison
KURA vs ABUS Comparison
Compare KURA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- ABUS
- Stock Information
- Founded
- KURA 2014
- ABUS N/A
- Country
- KURA United States
- ABUS United States
- Employees
- KURA N/A
- ABUS N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- ABUS Health Care
- Exchange
- KURA Nasdaq
- ABUS Nasdaq
- Market Cap
- KURA 592.7M
- ABUS 617.3M
- IPO Year
- KURA N/A
- ABUS N/A
- Fundamental
- Price
- KURA $6.38
- ABUS $3.48
- Analyst Decision
- KURA Strong Buy
- ABUS Strong Buy
- Analyst Count
- KURA 10
- ABUS 4
- Target Price
- KURA $25.50
- ABUS $5.50
- AVG Volume (30 Days)
- KURA 1.1M
- ABUS 953.7K
- Earning Date
- KURA 05-01-2025
- ABUS 03-27-2025
- Dividend Yield
- KURA N/A
- ABUS N/A
- EPS Growth
- KURA N/A
- ABUS N/A
- EPS
- KURA N/A
- ABUS N/A
- Revenue
- KURA $53,883,000.00
- ABUS $6,171,000.00
- Revenue This Year
- KURA $13.15
- ABUS N/A
- Revenue Next Year
- KURA $221.86
- ABUS $61.99
- P/E Ratio
- KURA N/A
- ABUS N/A
- Revenue Growth
- KURA N/A
- ABUS N/A
- 52 Week Low
- KURA $6.27
- ABUS $2.30
- 52 Week High
- KURA $23.48
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- KURA 30.98
- ABUS 57.45
- Support Level
- KURA $6.95
- ABUS $3.20
- Resistance Level
- KURA $8.04
- ABUS $3.45
- Average True Range (ATR)
- KURA 0.43
- ABUS 0.15
- MACD
- KURA -0.07
- ABUS 0.03
- Stochastic Oscillator
- KURA 6.21
- ABUS 72.73
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.